119 results
424B3
KA
Kineta Inc
13 Nov 23
Prospectus supplement
5:28pm
, technology and our discovery engine;
our commercialization, marketing and manufacturing capabilities and strategy;
the pricing and reimbursement of our
8-K
EX-10.1
h0l2cus51kyz7p1
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
5tk2fg2luo1p 6nqm7
5 Oct 23
Prospectus supplement for primary offering
10:47am
424B3
dxtgw1ct30yklg45o0
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-10.1
cqha87h8b
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
v05nq1hh kzjo
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.6
uqaxk3y0gju rvwwjq
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
81h1r
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
8x3bg7a
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
ghl1f86 ffgoa3
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm